---
id: streptogramins-quinupristin-dalfopristin_181
category: antimicrobials
tags: [streptogramins, quinupristin-dalfopristin, synercid, vref, enterococcus]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## Streptogramins - Quinupristin-Dalfopristin

**Q:** What is the mechanism, spectrum, and clinical use of quinupristin-dalfopristin (Synercid), and why is it rarely used today?

**A:**

## MECHANISM OF ACTION

**Mnemonic: "TWO-STEP-50S-SYNERGY"**

**Quinupristin-Dalfopristin = combination of 2 streptogramins (30:70 ratio):**

**Dalfopristin (Group A Streptogramin):**
- **Binds 50S ribosome** → distorts ribosome
- **Bacteriostatic alone**

**Quinupristin (Group B Streptogramin):**
- **Binds 50S ribosome** (at distorted site created by dalfopristin)
- **Blocks peptidyl transfer** → inhibits protein synthesis
- **Bacteriostatic alone**

**Combined Effect:**
- **Sequential binding** → **bactericidal** (synergy)
- **Similar mechanism to linezolid** (both bind 50S ribosome)

**Key Point:** **Two-step 50S inhibition** → synergistic bactericidal effect

---

## ANTIMICROBIAL SPECTRUM

**Mnemonic: "VRE-MRSA-LIMITED"**

### **Gram-Positive Coverage (EXCELLENT):**

**Enterococcus:**
- ***E. faecium*** (including vancomycin-resistant - **VRE**)
- **NO activity vs *E. faecalis*** (intrinsically resistant)

**Staphylococcus:**
- ***MRSA*** (excellent activity)
- **MSSA**

**Streptococcus:**
- **Streptococcus pneumoniae**
- **Streptococcus pyogenes**

### **Gram-Negative Coverage:**
- **NO activity** (does not penetrate outer membrane)

### **Anaerobes:**
- **Some activity** vs gram-positive anaerobes (Peptostreptococcus)

**Key Point:** ***E. faecium* VRE** (activity) | ***E. faecalis* NO activity** (intrinsically resistant)

---

## CLINICAL USES

**Mnemonic: "VRE-FAECIUM-ONLY"**

### **Primary Use:**

***Vancomycin-Resistant Enterococcus faecium* (VRE faecium):**
- **Bacteremia, endocarditis** (when daptomycin or linezolid not suitable)
- **Second-line** (after daptomycin, linezolid)

### **Why Rarely Used Today:**

**Better Alternatives for VRE:**
1. **Daptomycin** (better tolerated, bactericidal)
2. **Linezolid** (better tolerated, oral option)
3. **Tedizolid** (newer oxazolidinone)

**MRSA:**
- **NOT used** (vancomycin, daptomycin, linezolid preferred)

**Key Point:** **VRE faecium = only indication** (but daptomycin/linezolid preferred - better tolerated)

---

## DOSING & ADMINISTRATION

**Dose:** **7.5mg/kg IV Q8H** (based on quinupristin component)

**Administration:**
- **Central line preferred** (severe phlebitis with peripheral IV)
- **Infuse over 60 minutes** (via infusion pump)
- **Flush with D5W** (incompatible with saline)

**Key Point:** **Central line required** (severe phlebitis with peripheral IV)

---

## ADVERSE EFFECTS

**Mnemonic: "PHLEBITIS-MYALGIAS-ARTHRALGIAS-HEPATO"**

### **Common (>10%):**

**1. Phlebitis/Thrombophlebitis (70-80%):**
- **Severe** (peripheral IV intolerable)
- **Requires central line**

**2. Myalgias/Arthralgias (40-50%):**
- **Severe muscle/joint pain**
- **May require discontinuation** (10-20%)

### **Hepatotoxicity (10-20%):**
- **Elevated transaminases** (AST/ALT)
- **Usually reversible**

### **Infusion Reactions:**
- **Nausea, vomiting** (30-40%)

### **Drug Interactions:**

**CYP3A4 Inhibition:**
- **Inhibits CYP3A4** → increases levels of:
  - **Cyclosporine** (increased nephrotoxicity)
  - **Tacrolimus** (increased nephrotoxicity)
  - **Statins** (rhabdomyolysis risk)
  - **Midazolam, diazepam** (prolonged sedation)

**Key Point:** **Phlebitis = 70-80%** (central line required) | **Myalgias = 40-50%** (may require discontinuation)

---

## RESISTANCE MECHANISMS

**Mnemonic: "METHYLATION-EFFLUX-INACTIVATION"**

**Mechanisms:**
1. **Ribosomal methylation (erm genes):**
   - **Methylates 23S rRNA** → prevents binding
   - **Cross-resistance:** Macrolides, lincosamides (MLS resistance)
2. **Efflux pumps (msr genes):**
   - **Pumps drug out**
3. **Enzymatic inactivation:**
   - **Acetyltransferases** (inactivate quinupristin)

***E. faecalis* Intrinsic Resistance:**
- **Lactona se enzyme** (hydrolyzes dalfopristin - Group A component)
- **Only quinupristin active** → no synergy → NO bactericidal activity

**Key Point:** ***E. faecalis* intrinsically resistant** (lactonase degrades dalfopristin → no synergy)

---

## WHY RARELY USED TODAY

**Mnemonic: "BETTER-ALTERNATIVES-POOR-TOLERABILITY"**

### **Reasons:**

1. **Poor Tolerability:**
   - **Phlebitis = 70-80%** (central line required)
   - **Myalgias = 40-50%** (may require discontinuation)

2. **Better Alternatives for VRE:**
   - **Daptomycin** (bactericidal, better tolerated, once-daily dosing)
   - **Linezolid** (oral option, better tolerated)
   - **Tedizolid** (newer oxazolidinone - fewer adverse effects)

3. **Limited Spectrum:**
   - **NO *E. faecalis* activity** (most common Enterococcus species)
   - **Only *E. faecium*** (less common)

4. **Drug Interactions:**
   - **CYP3A4 inhibition** (problematic in transplant patients)

5. **IV Only:**
   - **No oral formulation** (linezolid has oral option)

**Key Point:** **Rarely used** (poor tolerability, better alternatives exist)

---

## COMPARISON: VRE TREATMENT OPTIONS

| **Agent** | **E. faecium VRE** | **E. faecalis VRE** | **Tolerability** | **Route** | **Bactericidal** |
|-----------|-------------------|---------------------|------------------|----------|------------------|
| **Daptomycin** | ✅ | ✅ | Good | IV | ✅ |
| **Linezolid** | ✅ | ✅ | Good | IV/PO | ❌ (static) |
| **Quinupristin-Dalfopristin** | ✅ | ❌ | **Poor** | IV | ✅ (faecium only) |
| **Tedizolid** | ✅ | ✅ | Good | IV/PO | ❌ (static) |

**Key Point:** **Daptomycin = preferred** (covers both *E. faecium* and *E. faecalis*, bactericidal, well-tolerated)

---

**Clinical Pearls:**
- **Two-step 50S inhibition** → synergistic bactericidal effect
- ***E. faecium* VRE** (activity) | ***E. faecalis* NO activity** (intrinsically resistant)
- **VRE faecium = only indication** (but daptomycin/linezolid preferred)
- **Central line required** (phlebitis = 70-80% with peripheral IV)
- **Myalgias = 40-50%** (may require discontinuation)
- **CYP3A4 inhibitor** (drug interactions with cyclosporine, tacrolimus, statins)
- ***E. faecalis* intrinsically resistant** (lactonase degrades dalfopristin)
- **Rarely used today** (poor tolerability, better alternatives exist)
- **Daptomycin = preferred for VRE** (covers both species, bactericidal, well-tolerated)

**Media:**

**Additional Resources:**
- **Sanford Guide:** Streptogramins
- **UpToDate:** Quinupristin-dalfopristin
- **IDSA Guidelines:** VRE treatment

**Sources:** [Sanford Guide], [UpToDate Q-D], [IDSA VRE Guidelines]
